Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMRNNASDAQ:BTMDNASDAQ:OCGNNASDAQ:STRO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$9.11-2.7%$9.78$7.08▼$20.60$187.07M1.3872,691 shs115,140 shsBTMDbiote$3.30-0.3%$3.92$3.04▼$8.44$180.54M1.17186,781 shs108,305 shsOCGNOcugen$0.68+4.0%$0.64$0.52▼$2.06$198.39M3.784.80 million shs3.49 million shsSTROSutro Biopharma$0.53-2.2%$1.08$0.52▼$5.17$44.54M1.7968,202 shs1.34 million shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin0.00%-2.04%-0.98%-18.37%-50.33%BTMDbiote0.00%-9.59%-21.80%-41.49%-40.22%OCGNOcugen0.00%-1.59%+23.77%-4.31%-52.82%STROSutro Biopharma0.00%-12.35%-35.67%-73.73%-86.11%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMRNAmarin0.2479 of 5 stars1.02.00.00.02.20.00.0BTMDbiote3.3782 of 5 stars3.52.00.00.04.23.31.3OCGNOcugen1.2916 of 5 stars3.51.00.00.02.60.00.0STROSutro Biopharma3.8953 of 5 stars4.12.00.04.70.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMRNAmarin 2.00Hold$7.00-23.16% DownsideBTMDbiote 3.00Buy$8.00142.42% UpsideOCGNOcugen 3.00Buy$6.33832.20% UpsideSTROSutro Biopharma 2.22Hold$6.631,154.73% UpsideCurrent Analyst Ratings BreakdownLatest STRO, OCGN, AMRN, and BTMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/17/2025AMRNAmarinThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSell ➝ Sell$20.00 ➝ $7.003/17/2025STROSutro BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$12.00 ➝ $2.003/14/2025STROSutro BiopharmaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$2.003/14/2025STROSutro BiopharmaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/14/2025STROSutro BiopharmaCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform3/14/2025STROSutro BiopharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral$8.00 ➝ $2.003/14/2025STROSutro BiopharmaBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Underperform$11.00 ➝ $1.003/13/2025BTMDbioteCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $8.003/6/2025OCGNOcugenChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$6.00 ➝ $7.003/6/2025OCGNOcugenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.002/13/2025OCGNOcugenChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00(Data available from 4/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMRNAmarin$228.61M0.82N/AN/A$1.35 per share6.75BTMDbiote$197.19M0.92$0.34 per share9.60($0.58) per share-5.69OCGNOcugen$4.06M48.93N/AN/A$0.16 per share4.25STROSutro Biopharma$62.04M0.72N/AN/A$2.45 per share0.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMRNAmarin-$59.11M-$4.00N/AN/AN/A-16.33%-7.22%-4.96%5/7/2025 (Estimated)BTMDbiote$3.32M$0.1812.696.11N/A5.20%-32.41%22.26%5/6/2025 (Estimated)OCGNOcugen-$63.08M-$0.19N/AN/AN/A-532.51%-154.75%-90.79%5/13/2025 (Estimated)STROSutro Biopharma-$106.79M-$3.02N/AN/AN/A-77.01%-101.89%-28.69%5/12/2025 (Estimated)Latest STRO, OCGN, AMRN, and BTMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025OCGNOcugen-$0.06N/AN/AN/AN/AN/A5/12/2025Q1 2025STROSutro Biopharma-$0.63N/AN/AN/A$11.61 millionN/A5/7/2025Q1 2025AMRNAmarin-$0.06N/AN/AN/AN/AN/A5/6/2025Q1 2025BTMDbiote$0.06N/AN/AN/A$47.25 millionN/A3/13/2025Q4 2024STROSutro Biopharma-$0.86-$2.96-$2.10-$0.89$10.44 million$14.00 million3/12/2025Q4 2024AMRNAmarin-$1.20-$2.40-$1.20-$0.12$32.37 million$62.31 million3/5/2025Q4 2024OCGNOcugen-$0.05-$0.05N/A-$0.05$0.30 million$0.76 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMRNAmarinN/AN/AN/AN/AN/ABTMDbioteN/AN/AN/AN/AN/AOCGNOcugenN/AN/AN/AN/AN/ASTROSutro BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMRNAmarinN/A3.232.11BTMDbioteN/A1.501.16OCGNOcugen0.042.582.58STROSutro BiopharmaN/A3.093.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMRNAmarin22.25%BTMDbiote21.68%OCGNOcugen10.27%STROSutro Biopharma96.99%Insider OwnershipCompanyInsider OwnershipAMRNAmarin1.96%BTMDbiote24.00%OCGNOcugen4.29%STROSutro Biopharma5.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMRNAmarin36020.53 million402.62 millionOptionableBTMDbiote19454.71 million46.78 millionNot OptionableOCGNOcugen80292.01 million278.82 millionOptionableSTROSutro Biopharma24084.36 million77.59 millionOptionableSTRO, OCGN, AMRN, and BTMD HeadlinesRecent News About These CompaniesWhy Sutro Biopharma, Inc.’s (STRO) Stock Is Down 10.88%April 1, 2025 | aaii.comHC Wainwright Lifts Earnings Estimates for Sutro BiopharmaMarch 20, 2025 | marketbeat.comWhy Sutro Biopharma, Inc.’s (STRO) Stock Is Up 15.10%March 18, 2025 | aaii.comSutro Biopharma downgraded to Neutral from Buy at H.C. WainwrightMarch 17, 2025 | markets.businessinsider.comHC Wainwright & Co. Downgrades Sutro Biopharma (STRO)March 17, 2025 | msn.comSutro Biopharma presents expanded data from REFRalphaME-01 trialMarch 17, 2025 | markets.businessinsider.comSutro Biopharma Presents Data from Dose-Optimization Portion of REFRaME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025March 15, 2025 | tmcnet.comSutro Biopharma Presents Data from Dose-Optimization Portion of REFRaME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025March 15, 2025 | tmcnet.comSutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025March 15, 2025 | globenewswire.comWhy Sutro Biopharma, Inc.’s (STRO) Stock Is Down 35.19%March 15, 2025 | aaii.comWedbush Downgrades Sutro Biopharma (STRO)March 15, 2025 | msn.comSutro Biopharma downgraded to Neutral from Overweight at Piper SandlerMarch 14, 2025 | markets.businessinsider.comSutro Cuts Half of Staff, Deprioritizes ADC in Strategic ReviewMarch 14, 2025 | biospace.comNew ADC focus as Sutro slashes workforce, drops lead drugMarch 14, 2025 | thepharmaletter.comSutro drops as portfolio review leads to downgradesMarch 14, 2025 | msn.comSutro Biopharma, Inc.: Sutro Biopharma Reports Full Year 2024 Financial Results and Business HighlightsMarch 14, 2025 | finanznachrichten.deSutro Biopharma, Inc.: Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC PipelineMarch 14, 2025 | finanznachrichten.deSutro discards CEO, 50% of staff, sole clinical-stage ADC and manufacturing site to save cashMarch 14, 2025 | fiercebiotech.comSutro puts lead ADC on hold, cuts staff and changes CEOMarch 14, 2025 | pharmaphorum.comSutro Biopharma downgraded to Neutral from Outperform at WedbushMarch 14, 2025 | markets.businessinsider.comSutro Biopharma double downgraded at BofA after luvelta deprioritizedMarch 14, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Stocks Near 52-Week Lows With Strong Rebound PotentialBy Gabriel Osorio-Mazilli | March 31, 2025View 3 Stocks Near 52-Week Lows With Strong Rebound Potential5 Hot Stock Buys for Investors in AprilBy Thomas Hughes | April 1, 2025View 5 Hot Stock Buys for Investors in April5 Reasons the S&P 500 Could Rebound Strongly in 2025By Thomas Hughes | April 3, 2025View 5 Reasons the S&P 500 Could Rebound Strongly in 2025Why NVIDIA Stock Could Soar Despite Wall Street DowngradesBy Thomas Hughes | April 14, 2025View Why NVIDIA Stock Could Soar Despite Wall Street DowngradesEnergy Transfer: Powering Data With Dividends and DiversificationBy Jeffrey Neal Johnson | March 26, 2025View Energy Transfer: Powering Data With Dividends and DiversificationSTRO, OCGN, AMRN, and BTMD Company DescriptionsAmarin NASDAQ:AMRN$9.11 -0.25 (-2.67%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$9.38 +0.27 (+2.96%) As of 04/17/2025 05:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.biote NASDAQ:BTMD$3.30 -0.01 (-0.30%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$3.40 +0.10 (+3.03%) As of 04/17/2025 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.Ocugen NASDAQ:OCGN$0.68 +0.03 (+4.01%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$0.67 -0.01 (-0.79%) As of 04/17/2025 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.Sutro Biopharma NASDAQ:STRO$0.53 -0.01 (-2.22%) Closing price 04/17/2025 03:59 PM EasternExtended Trading$0.53 +0.01 (+0.95%) As of 04/17/2025 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/14 - 04/18 Archer Aviation Unveils NYC Network Ahead of Key Earnings Report Joby Aviation Stock Presents an Opportunity in the Turbulence Tariff Exemptions Set the Stage for a Taiwan Semiconductor Rally Tariff-Resistant Kinder Morgan Is a Good Buy in 2025 Rocket Lab's Growth Potential Gains Altitude on Defense News Broadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk 3 Mid-Cap to Mega-Cap Stocks Have Announced Significant Buybacks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
